According to the ELN 2022 risk stratification, NPM1-mutated AML without adverse-risk cytogenetic abnormalities can be classified either as low risk or as intermediate risk, according to the presence of an FLT3-ITD mutation [3]. This evidence concerns the gene FLT3 and acute myeloid leukemia.